胆道癌
医学
化疗
佐剂
胆道
辅助化疗
切除术
癌症
肿瘤科
内科学
吉西他滨
外科
乳腺癌
作者
Young Saing Kim,Chi‐Young Jeong,Haa‐Na Song,Tae Hyo Kim,Hong Jun Kim,Young Joon Lee,Soon‐Chan Hong
出处
期刊:癌症:英文版
日期:2017-01-13
卷期号:36 (1): 9-9
被引量:8
标识
DOI:10.1186/s40880-017-0182-y
摘要
BACKGROUND: The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection. METHODS: We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection. RESULTS: A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. However, for patients with stages II and III BTC, chemotherapy significantly improved 5-year OS rate (52.4% vs. 35.6%, P = 0.002) and 3-year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation. CONCLUSION: Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection.
科研通智能强力驱动
Strongly Powered by AbleSci AI